News RSS Bioethics News.

09/14/2018

Drug executive: It’s a ‘moral requirement’ to charge patients the highest price

External Link - Source: Los Angeles Times

In his interview with the Financial Times published Tuesday, Mulye defended Martin Shkreli, the former drug company CEO who became the face of the industry’s profiteering in 2015 when he jacked up the price of a generic anti-parasitic drug needed by HIV patients by more than 5,000%. “I agree with Martin Shkreli that when he raised the price of his drug he was within his rights because he had to reward his shareholders,” Mulye told the FT. (Shkreli is currently serving a prison term on fraud charges unrelated to the price hike.)

This entry was posted in Clinical Ethics, Health Care, Pharmaceuticals and tagged , , . Bookmark the permalink.